Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ; Cooperating investigators of the Dutch TEAM trial. van Nes JG, et al. Among authors: de jong rs. Ann Oncol. 2010 May;21(5):974-82. doi: 10.1093/annonc/mdp419. Epub 2009 Oct 29. Ann Oncol. 2010. PMID: 19875752 Free article. Clinical Trial.
A microglia-containing cerebral organoid model to study early life immune challenges.
Buonfiglioli A, Kübler R, Missall R, De Jong R, Chan S, Haage V, Wendt S, Lin AJ, Mattei D, Graziani M, Latour B, Gigase F, Chiu R, Zhang Y, Nygaard HB, De Jager PL, De Witte LD. Buonfiglioli A, et al. Brain Behav Immun. 2024 Nov 3;123:1127-1146. doi: 10.1016/j.bbi.2024.11.008. Online ahead of print. Brain Behav Immun. 2024. PMID: 39500415
A microglia-containing cerebral organoid model to study early life immune challenges.
Buonfiglioli A, Kübler R, Missall R, De Jong R, Chan S, Haage V, Wendt S, Lin AJ, Mattei D, Graziani M, Latour B, Gigase F, Nygaard HB, De Jager PL, De Witte LD. Buonfiglioli A, et al. bioRxiv [Preprint]. 2024 May 29:2024.05.24.595814. doi: 10.1101/2024.05.24.595814. bioRxiv. 2024. Update in: Brain Behav Immun. 2024 Nov 3;123:1127-1146. doi: 10.1016/j.bbi.2024.11.008. PMID: 38826204 Free PMC article. Updated. Preprint.
The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer.
Derksen JWG, Kurk SA, Peeters PHM, Dorresteijn B, Jourdan M, van der Velden AMT, Nieboer P, de Jong RS, Honkoop AH, Punt CJA, Koopman M, May AM. Derksen JWG, et al. Among authors: de jong rs. J Cachexia Sarcopenia Muscle. 2020 Aug;11(4):919-928. doi: 10.1002/jcsm.12562. Epub 2020 Feb 27. J Cachexia Sarcopenia Muscle. 2020. PMID: 32107889 Free PMC article.
Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.
Meulendijks D, de Groot JW, Los M, Boers JE, Beerepoot LV, Polee MB, Beeker A, Portielje JE, Goey SH, de Jong RS, Vanhoutvin SA, Kuiper M, Sikorska K, Pluim D, Beijnen JH, Schellens JH, Grootscholten C, Tesselaar ME, Cats A. Meulendijks D, et al. Among authors: de jong rs. Cancer. 2016 May 1;122(9):1434-43. doi: 10.1002/cncr.29864. Epub 2016 Mar 11. Cancer. 2016. PMID: 26970343 Free article. Clinical Trial.
Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.
Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A. Meulendijks D, et al. Among authors: de jong rs. Invest New Drugs. 2016 Feb;34(1):119-28. doi: 10.1007/s10637-015-0309-4. Epub 2015 Dec 8. Invest New Drugs. 2016. PMID: 26643663 Clinical Trial.
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Loosveld OJ, van Bochove A, Sinnige HA, Creemers GM, Tesselaar ME, Slee PHTJ, Werter MJ, Mol L, Dalesio O, Punt CJ. Koopman M, et al. Among authors: de jong rs. Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1. Lancet. 2007. PMID: 17630036 Clinical Trial.
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.
Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, de Jong RS, Rodenburg CJ, Vreugdenhil G, Akkermans-Vogelaar JM, Punt CJ. Koopman M, et al. Among authors: de jong rs. Ann Oncol. 2006 Oct;17(10):1523-8. doi: 10.1093/annonc/mdl179. Epub 2006 Jul 27. Ann Oncol. 2006. PMID: 16873425 Free article. Clinical Trial.
25 results